réservé à la recherche
N° Cat.S1109
| Cibles apparentées | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Autre PLK Inhibiteurs | Volasertib (BI6727) Rigosertib (ON-01910) GSK461364 Onvansertib (NMS-1286937, NMS-P937) CFI-400945 HMN-214 Ro3280 SBE 13 HCl MLN0905 Centrinone (LCR-263) |
| Lignées cellulaires | Type dessai | Concentration | Temps dincubation | Formulation | Description de lactivité | PMID |
|---|---|---|---|---|---|---|
| PSN1 | Growth Inhibition Assay | IC50=0.00776 μM | SANGER | |||
| ACN | Growth Inhibition Assay | IC50=0.00843 μM | SANGER | |||
| TE-8 | Growth Inhibition Assay | IC50=0.00941 μM | SANGER | |||
| LC-2-ad | Growth Inhibition Assay | IC50=0.01093 μM | SANGER | |||
| ALL-PO | Growth Inhibition Assay | IC50=0.013 μM | SANGER | |||
| EW-16 | Growth Inhibition Assay | IC50=0.01336 μM | SANGER | |||
| KM12 | Growth Inhibition Assay | IC50=0.01348 μM | SANGER | |||
| GI-1 | Growth Inhibition Assay | IC50=0.01383 μM | SANGER | |||
| LS-411N | Growth Inhibition Assay | IC50=0.01407 μM | SANGER | |||
| ES8 | Growth Inhibition Assay | IC50=0.01494 μM | SANGER | |||
| SNU-C2B | Growth Inhibition Assay | IC50=0.01526 μM | SANGER | |||
| CESS | Growth Inhibition Assay | IC50=0.01602 μM | SANGER | |||
| 697 | Growth Inhibition Assay | IC50=0.01668 μM | SANGER | |||
| NCI-H1963 | Growth Inhibition Assay | IC50=0.01673 μM | SANGER | |||
| IA-LM | Growth Inhibition Assay | IC50=0.01688 μM | SANGER | |||
| SW954 | Growth Inhibition Assay | IC50=0.01705 μM | SANGER | |||
| RL95-2 | Growth Inhibition Assay | IC50=0.01738 μM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=0.0177 μM | SANGER | |||
| OCUB-M | Growth Inhibition Assay | IC50=0.01826 μM | SANGER | |||
| RKO | Growth Inhibition Assay | IC50=0.01987 μM | SANGER | |||
| LOUCY | Growth Inhibition Assay | IC50=0.0205 μM | SANGER | |||
| NOS-1 | Growth Inhibition Assay | IC50=0.02093 μM | SANGER | |||
| A4-Fuk | Growth Inhibition Assay | IC50=0.02218 μM | SANGER | |||
| A388 | Growth Inhibition Assay | IC50=0.02227 μM | SANGER | |||
| TE-9 | Growth Inhibition Assay | IC50=0.02261 μM | SANGER | |||
| KURAMOCHI | Growth Inhibition Assay | IC50=0.02285 μM | SANGER | |||
| KALS-1 | Growth Inhibition Assay | IC50=0.02338 μM | SANGER | |||
| HOP-62 | Growth Inhibition Assay | IC50=0.0242 μM | SANGER | |||
| RPMI-8402 | Growth Inhibition Assay | IC50=0.02508 μM | SANGER | |||
| TE-1 | Growth Inhibition Assay | IC50=0.02512 μM | SANGER | |||
| CCRF-CEM | Growth Inhibition Assay | IC50=0.02543 μM | SANGER | |||
| HUTU-80 | Growth Inhibition Assay | IC50=0.02624 μM | SANGER | |||
| NCI-H1648 | Growth Inhibition Assay | IC50=0.02647 μM | SANGER | |||
| HCE-4 | Growth Inhibition Assay | IC50=0.02682 μM | SANGER | |||
| ETK-1 | Growth Inhibition Assay | IC50=0.02736 μM | SANGER | |||
| TE-15 | Growth Inhibition Assay | IC50=0.02738 μM | SANGER | |||
| BE-13 | Growth Inhibition Assay | IC50=0.0274 μM | SANGER | |||
| KE-37 | Growth Inhibition Assay | IC50=0.02741 μM | SANGER | |||
| NCI-H1355 | Growth Inhibition Assay | IC50=0.02783 μM | SANGER | |||
| TE-11 | Growth Inhibition Assay | IC50=0.02809 μM | SANGER | |||
| BL-70 | Growth Inhibition Assay | IC50=0.02857 μM | SANGER | |||
| ES6 | Growth Inhibition Assay | IC50=0.02881 μM | SANGER | |||
| GT3TKB | Growth Inhibition Assay | IC50=0.02953 μM | SANGER | |||
| LB647-SCLC | Growth Inhibition Assay | IC50=0.03195 μM | SANGER | |||
| NB13 | Growth Inhibition Assay | IC50=0.03316 μM | SANGER | |||
| ST486 | Growth Inhibition Assay | IC50=0.03337 μM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=0.03343 μM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=0.03399 μM | SANGER | |||
| ES4 | Growth Inhibition Assay | IC50=0.03463 μM | SANGER | |||
| SK-NEP-1 | Growth Inhibition Assay | IC50=0.03499 μM | SANGER | |||
| Becker | Growth Inhibition Assay | IC50=0.03555 μM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=0.03748 μM | SANGER | |||
| SK-UT-1 | Growth Inhibition Assay | IC50=0.03774 μM | SANGER | |||
| SW982 | Growth Inhibition Assay | IC50=0.0379 μM | SANGER | |||
| TE-10 | Growth Inhibition Assay | IC50=0.04046 μM | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | IC50=0.04059 μM | SANGER | |||
| KP-N-YS | Growth Inhibition Assay | IC50=0.04085 μM | SANGER | |||
| BL-41 | Growth Inhibition Assay | IC50=0.04125 μM | SANGER | |||
| MZ1-PC | Growth Inhibition Assay | IC50=0.04127 μM | SANGER | |||
| PF-382 | Growth Inhibition Assay | IC50=0.04198 μM | SANGER | |||
| MOLT-13 | Growth Inhibition Assay | IC50=0.04238 μM | SANGER | |||
| HCC1599 | Growth Inhibition Assay | IC50=0.04258 μM | SANGER | |||
| IST-MEL1 | Growth Inhibition Assay | IC50=0.04442 μM | SANGER | |||
| LU-139 | Growth Inhibition Assay | IC50=0.04442 μM | SANGER | |||
| MS-1 | Growth Inhibition Assay | IC50=0.04701 μM | SANGER | |||
| MFH-ino | Growth Inhibition Assay | IC50=0.05003 μM | SANGER | |||
| IMR-5 | Growth Inhibition Assay | IC50=0.05021 μM | SANGER | |||
| TE-5 | Growth Inhibition Assay | IC50=0.05063 μM | SANGER | |||
| DJM-1 | Growth Inhibition Assay | IC50=0.05142 μM | SANGER | |||
| NB17 | Growth Inhibition Assay | IC50=0.05207 μM | SANGER | |||
| KARPAS-45 | Growth Inhibition Assay | IC50=0.05358 μM | SANGER | |||
| TGBC1TKB | Growth Inhibition Assay | IC50=0.05405 μM | SANGER | |||
| ML-2 | Growth Inhibition Assay | IC50=0.05414 μM | SANGER | |||
| no-10 | Growth Inhibition Assay | IC50=0.05474 μM | SANGER | |||
| CTV-1 | Growth Inhibition Assay | IC50=0.05502 μM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=0.0552 μM | SANGER | |||
| HC-1 | Growth Inhibition Assay | IC50=0.05597 μM | SANGER | |||
| TE-12 | Growth Inhibition Assay | IC50=0.05613 μM | SANGER | |||
| KY821 | Growth Inhibition Assay | IC50=0.05632 μM | SANGER | |||
| TALL-1 | Growth Inhibition Assay | IC50=0.05708 μM | SANGER | |||
| DEL | Growth Inhibition Assay | IC50=0.05709 μM | SANGER | |||
| TE-6 | Growth Inhibition Assay | IC50=0.05722 μM | SANGER | |||
| SK-LMS-1 | Growth Inhibition Assay | IC50=0.05805 μM | SANGER | |||
| EW-1 | Growth Inhibition Assay | IC50=0.05837 μM | SANGER | |||
| 8-MG-BA | Growth Inhibition Assay | IC50=0.05851 μM | SANGER | |||
| NALM-6 | Growth Inhibition Assay | IC50=0.05973 μM | SANGER | |||
| LB771-HNC | Growth Inhibition Assay | IC50=0.05979 μM | SANGER | |||
| HT-144 | Growth Inhibition Assay | IC50=0.0613 μM | SANGER | |||
| KM-H2 | Growth Inhibition Assay | IC50=0.06221 μM | SANGER | |||
| SF268 | Growth Inhibition Assay | IC50=0.06286 μM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=0.06304 μM | SANGER | |||
| MHH-PREB-1 | Growth Inhibition Assay | IC50=0.06319 μM | SANGER | |||
| ATN-1 | Growth Inhibition Assay | IC50=0.06345 μM | SANGER | |||
| BB30-HNC | Growth Inhibition Assay | IC50=0.06436 μM | SANGER | |||
| CPC-N | Growth Inhibition Assay | IC50=0.06524 μM | SANGER | |||
| NB1 | Growth Inhibition Assay | IC50=0.06613 μM | SANGER | |||
| KS-1 | Growth Inhibition Assay | IC50=0.06748 μM | SANGER | |||
| RXF393 | Growth Inhibition Assay | IC50=0.06764 μM | SANGER | |||
| IST-SL2 | Growth Inhibition Assay | IC50=0.07004 μM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=0.07286 μM | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | IC50=0.07475 μM | SANGER | |||
| NCI-H1581 | Growth Inhibition Assay | IC50=0.07478 μM | SANGER | |||
| U-266 | Growth Inhibition Assay | IC50=0.07497 μM | SANGER | |||
| DMS-114 | Growth Inhibition Assay | IC50=0.07528 μM | SANGER | |||
| NCI-H187 | Growth Inhibition Assay | IC50=0.07726 μM | SANGER | |||
| SW962 | Growth Inhibition Assay | IC50=0.07839 μM | SANGER | |||
| MONO-MAC-6 | Growth Inhibition Assay | IC50=0.07986 μM | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | IC50=0.08121 μM | SANGER | |||
| KNS-42 | Growth Inhibition Assay | IC50=0.08161 μM | SANGER | |||
| CMK | Growth Inhibition Assay | IC50=0.08225 μM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=0.08225 μM | SANGER | |||
| Daudi | Growth Inhibition Assay | IC50=0.08256 μM | SANGER | |||
| NCI-H510A | Growth Inhibition Assay | IC50=0.08336 μM | SANGER | |||
| LB831-BLC | Growth Inhibition Assay | IC50=0.08561 μM | SANGER | |||
| HEL | Growth Inhibition Assay | IC50=0.08668 μM | SANGER | |||
| LU-134-A | Growth Inhibition Assay | IC50=0.08708 μM | SANGER | |||
| NCI-H1694 | Growth Inhibition Assay | IC50=0.08744 μM | SANGER | |||
| KGN | Growth Inhibition Assay | IC50=0.08759 μM | SANGER | |||
| A253 | Growth Inhibition Assay | IC50=0.08822 μM | SANGER | |||
| DG-75 | Growth Inhibition Assay | IC50=0.08922 μM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=0.08983 μM | SANGER | |||
| NCI-SNU-5 | Growth Inhibition Assay | IC50=0.09258 μM | SANGER | |||
| ONS-76 | Growth Inhibition Assay | IC50=0.09276 μM | SANGER | |||
| NCI-H446 | Growth Inhibition Assay | IC50=0.09462 μM | SANGER | |||
| COR-L279 | Growth Inhibition Assay | IC50=0.09556 μM | SANGER | |||
| Calu-6 | Growth Inhibition Assay | IC50=0.09598 μM | SANGER | |||
| BC-3 | Growth Inhibition Assay | IC50=0.09662 μM | SANGER | |||
| NCI-H2126 | Growth Inhibition Assay | IC50=0.09791 μM | SANGER | |||
| NCI-H1882 | Growth Inhibition Assay | IC50=0.09809 μM | SANGER | |||
| BB65-RCC | Growth Inhibition Assay | IC50=0.10294 μM | SANGER | |||
| DU-4475 | Growth Inhibition Assay | IC50=0.10407 μM | SANGER | |||
| NCI-H526 | Growth Inhibition Assay | IC50=0.1044 μM | SANGER | |||
| NEC8 | Growth Inhibition Assay | IC50=0.10525 μM | SANGER | |||
| NCI-H1304 | Growth Inhibition Assay | IC50=0.10594 μM | SANGER | |||
| L-540 | Growth Inhibition Assay | IC50=0.10708 μM | SANGER | |||
| NCI-SNU-16 | Growth Inhibition Assay | IC50=0.10742 μM | SANGER | |||
| HD-MY-Z | Growth Inhibition Assay | IC50=0.10856 μM | SANGER | |||
| K-562 | Growth Inhibition Assay | IC50=0.10858 μM | SANGER | |||
| JAR | Growth Inhibition Assay | IC50=0.10925 μM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=0.1105 μM | SANGER | |||
| L-363 | Growth Inhibition Assay | IC50=0.11079 μM | SANGER | |||
| BV-173 | Growth Inhibition Assay | IC50=0.11243 μM | SANGER | |||
| NCI-H524 | Growth Inhibition Assay | IC50=0.11274 μM | SANGER | |||
| EoL-1-cell | Growth Inhibition Assay | IC50=0.11672 μM | SANGER | |||
| K052 | Growth Inhibition Assay | IC50=0.11712 μM | SANGER | |||
| TK10 | Growth Inhibition Assay | IC50=0.11728 μM | SANGER | |||
| KU812 | Growth Inhibition Assay | IC50=0.12044 μM | SANGER | |||
| RPMI-8226 | Growth Inhibition Assay | IC50=0.12052 μM | SANGER | |||
| MZ7-mel | Growth Inhibition Assay | IC50=0.12237 μM | SANGER | |||
| SK-PN-DW | Growth Inhibition Assay | IC50=0.12287 μM | SANGER | |||
| SR | Growth Inhibition Assay | IC50=0.12441 μM | SANGER | |||
| RPMI-6666 | Growth Inhibition Assay | IC50=0.12743 μM | SANGER | |||
| no-11 | Growth Inhibition Assay | IC50=0.12869 μM | SANGER | |||
| EW-3 | Growth Inhibition Assay | IC50=0.12893 μM | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | IC50=0.13187 μM | SANGER | |||
| HT | Growth Inhibition Assay | IC50=0.13574 μM | SANGER | |||
| KP-N-RT-BM-1 | Growth Inhibition Assay | IC50=0.13612 μM | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | IC50=0.137 μM | SANGER | |||
| NCCIT | Growth Inhibition Assay | IC50=0.13939 μM | SANGER | |||
| MLMA | Growth Inhibition Assay | IC50=0.14167 μM | SANGER | |||
| LP-1 | Growth Inhibition Assay | IC50=0.1424 μM | SANGER | |||
| CAL-148 | Growth Inhibition Assay | IC50=0.14483 μM | SANGER | |||
| GB-1 | Growth Inhibition Assay | IC50=0.14526 μM | SANGER | |||
| COR-L88 | Growth Inhibition Assay | IC50=0.14802 μM | SANGER | |||
| NKM-1 | Growth Inhibition Assay | IC50=0.14906 μM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=0.15462 μM | SANGER | |||
| SH-4 | Growth Inhibition Assay | IC50=0.15466 μM | SANGER | |||
| EM-2 | Growth Inhibition Assay | IC50=0.15467 μM | SANGER | |||
| TGBC24TKB | Growth Inhibition Assay | IC50=0.15659 μM | SANGER | |||
| SCLC-21H | Growth Inhibition Assay | IC50=0.15702 μM | SANGER | |||
| COLO-684 | Growth Inhibition Assay | IC50=0.15721 μM | SANGER | |||
| KINGS-1 | Growth Inhibition Assay | IC50=0.1591 μM | SANGER | |||
| LS-123 | Growth Inhibition Assay | IC50=0.15917 μM | SANGER | |||
| MC116 | Growth Inhibition Assay | IC50=0.16158 μM | SANGER | |||
| SU-DHL-1 | Growth Inhibition Assay | IC50=0.16206 μM | SANGER | |||
| NCI-H64 | Growth Inhibition Assay | IC50=0.16347 μM | SANGER | |||
| HCE-T | Growth Inhibition Assay | IC50=0.16504 μM | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | IC50=0.16949 μM | SANGER | |||
| ARH-77 | Growth Inhibition Assay | IC50=0.17379 μM | SANGER | |||
| DOHH-2 | Growth Inhibition Assay | IC50=0.17672 μM | SANGER | |||
| COLO-320-HSR | Growth Inhibition Assay | IC50=0.18154 μM | SANGER | |||
| NB6 | Growth Inhibition Assay | IC50=0.18566 μM | SANGER | |||
| L-428 | Growth Inhibition Assay | IC50=0.18813 μM | SANGER | |||
| SNB75 | Growth Inhibition Assay | IC50=0.18824 μM | SANGER | |||
| NCI-H2141 | Growth Inhibition Assay | IC50=0.19011 μM | SANGER | |||
| KARPAS-299 | Growth Inhibition Assay | IC50=0.19241 μM | SANGER | |||
| LC4-1 | Growth Inhibition Assay | IC50=0.19502 μM | SANGER | |||
| UACC-257 | Growth Inhibition Assay | IC50=0.19947 μM | SANGER | |||
| EVSA-T | Growth Inhibition Assay | IC50=0.20312 μM | SANGER | |||
| JiyoyeP-2003 | Growth Inhibition Assay | IC50=0.20477 μM | SANGER | |||
| NCI-H720 | Growth Inhibition Assay | IC50=0.20525 μM | SANGER | |||
| GAK | Growth Inhibition Assay | IC50=0.21189 μM | SANGER | |||
| HH | Growth Inhibition Assay | IC50=0.21405 μM | SANGER | |||
| NCI-H1436 | Growth Inhibition Assay | IC50=0.21464 μM | SANGER | |||
| GR-ST | Growth Inhibition Assay | IC50=0.21488 μM | SANGER | |||
| BC-1 | Growth Inhibition Assay | IC50=0.22616 μM | SANGER | |||
| SIG-M5 | Growth Inhibition Assay | IC50=0.22727 μM | SANGER | |||
| NCI-H345 | Growth Inhibition Assay | IC50=0.23805 μM | SANGER | |||
| OPM-2 | Growth Inhibition Assay | IC50=0.23882 μM | SANGER | |||
| LB1047-RCC | Growth Inhibition Assay | IC50=0.2441 μM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=0.24493 μM | SANGER | |||
| A3-KAW | Growth Inhibition Assay | IC50=0.25341 μM | SANGER | |||
| SF126 | Growth Inhibition Assay | IC50=0.25383 μM | SANGER | |||
| KARPAS-422 | Growth Inhibition Assay | IC50=0.25435 μM | SANGER | |||
| MEG-01 | Growth Inhibition Assay | IC50=0.25673 μM | SANGER | |||
| NCI-H209 | Growth Inhibition Assay | IC50=0.26374 μM | SANGER | |||
| SBC-1 | Growth Inhibition Assay | IC50=0.265 μM | SANGER | |||
| K5 | Growth Inhibition Assay | IC50=0.26984 μM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=0.27155 μM | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | IC50=0.28217 μM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=0.29238 μM | SANGER | |||
| SW684 | Growth Inhibition Assay | IC50=0.30047 μM | SANGER | |||
| MV-4-11 | Growth Inhibition Assay | IC50=0.30788 μM | SANGER | |||
| LAN-6 | Growth Inhibition Assay | IC50=0.31572 μM | SANGER | |||
| RH-1 | Growth Inhibition Assay | IC50=0.31871 μM | SANGER | |||
| CP66-MEL | Growth Inhibition Assay | IC50=0.31878 μM | SANGER | |||
| EC-GI-10 | Growth Inhibition Assay | IC50=0.32987 μM | SANGER | |||
| GDM-1 | Growth Inhibition Assay | IC50=0.33059 μM | SANGER | |||
| IST-SL1 | Growth Inhibition Assay | IC50=0.34914 μM | SANGER | |||
| KMOE-2 | Growth Inhibition Assay | IC50=0.35175 μM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=0.35544 μM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=0.37814 μM | SANGER | |||
| DSH1 | Growth Inhibition Assay | IC50=0.38631 μM | SANGER | |||
| LS-1034 | Growth Inhibition Assay | IC50=0.38954 μM | SANGER | |||
| LB373-MEL-D | Growth Inhibition Assay | IC50=0.39197 μM | SANGER | |||
| GOTO | Growth Inhibition Assay | IC50=0.42118 μM | SANGER | |||
| MRK-nu-1 | Growth Inhibition Assay | IC50=0.42205 μM | SANGER | |||
| SK-MM-2 | Growth Inhibition Assay | IC50=0.43442 μM | SANGER | |||
| BOKU | Growth Inhibition Assay | IC50=0.43792 μM | SANGER | |||
| NOMO-1 | Growth Inhibition Assay | IC50=0.4386 μM | SANGER | |||
| J-RT3-T3-5 | Growth Inhibition Assay | IC50=0.44878 μM | SANGER | |||
| COLO-668 | Growth Inhibition Assay | IC50=0.45668 μM | SANGER | |||
| SF539 | Growth Inhibition Assay | IC50=0.48684 μM | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | IC50=0.49703 μM | SANGER | |||
| TE-441-T | Growth Inhibition Assay | IC50=0.5012 μM | SANGER | |||
| MDA-MB-134-VI | Growth Inhibition Assay | IC50=0.50921 μM | SANGER | |||
| SCC-3 | Growth Inhibition Assay | IC50=0.51873 μM | SANGER | |||
| KLE | Growth Inhibition Assay | IC50=0.52171 μM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=0.52525 μM | SANGER | |||
| NCI-H1417 | Growth Inhibition Assay | IC50=0.53435 μM | SANGER | |||
| NCI-H2081 | Growth Inhibition Assay | IC50=0.58611 μM | SANGER | |||
| NCI-H1522 | Growth Inhibition Assay | IC50=0.59383 μM | SANGER | |||
| NCI-H889 | Growth Inhibition Assay | IC50=0.59844 μM | SANGER | |||
| CGTH-W-1 | Growth Inhibition Assay | IC50=0.60755 μM | SANGER | |||
| EB-3 | Growth Inhibition Assay | IC50=0.61153 μM | SANGER | |||
| D-336MG | Growth Inhibition Assay | IC50=0.61791 μM | SANGER | |||
| LC-1F | Growth Inhibition Assay | IC50=0.62592 μM | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | IC50=0.63801 μM | SANGER | |||
| SK-N-FI | Growth Inhibition Assay | IC50=0.6391 μM | SANGER | |||
| NCI-H69 | Growth Inhibition Assay | IC50=0.64879 μM | SANGER | |||
| SCH | Growth Inhibition Assay | IC50=0.66023 μM | SANGER | |||
| LS-513 | Growth Inhibition Assay | IC50=0.67259 μM | SANGER | |||
| CP67-MEL | Growth Inhibition Assay | IC50=0.67596 μM | SANGER | |||
| GCIY | Growth Inhibition Assay | IC50=0.70363 μM | SANGER | |||
| SHP-77 | Growth Inhibition Assay | IC50=0.70734 μM | SANGER | |||
| EHEB | Growth Inhibition Assay | IC50=0.71854 μM | SANGER | |||
| D-247MG | Growth Inhibition Assay | IC50=0.73232 μM | SANGER | |||
| Raji | Growth Inhibition Assay | IC50=0.74989 μM | SANGER | |||
| MPP-89 | Growth Inhibition Assay | IC50=0.75978 μM | SANGER | |||
| EKVX | Growth Inhibition Assay | IC50=0.79073 μM | SANGER | |||
| HCC2218 | Growth Inhibition Assay | IC50=0.79131 μM | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | IC50=0.81011 μM | SANGER | |||
| HCC2157 | Growth Inhibition Assay | IC50=0.84951 μM | SANGER | |||
| BT-474 | Growth Inhibition Assay | IC50=0.88854 μM | SANGER | |||
| NCI-H748 | Growth Inhibition Assay | IC50=0.912 μM | SANGER | |||
| EW-24 | Growth Inhibition Assay | IC50=0.92002 μM | SANGER | |||
| D-263MG | Growth Inhibition Assay | IC50=0.94512 μM | SANGER | |||
| OMC-1 | Growth Inhibition Assay | IC50=0.96373 μM | SANGER | |||
| NCI-H2196 | Growth Inhibition Assay | IC50=0.97777 μM | SANGER | |||
| HAL-01 | Growth Inhibition Assay | IC50=0.99872 μM | SANGER | |||
| NCI-H2107 | Growth Inhibition Assay | IC50=1.01854 μM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=1.08051 μM | SANGER | |||
| NCI-H1395 | Growth Inhibition Assay | IC50=1.1067 μM | SANGER | |||
| CHP-126 | Growth Inhibition Assay | IC50=1.16199 μM | SANGER | |||
| NB69 | Growth Inhibition Assay | IC50=1.26148 μM | SANGER | |||
| CAS-1 | Growth Inhibition Assay | IC50=1.34231 μM | SANGER | |||
| JVM-3 | Growth Inhibition Assay | IC50=1.47855 μM | SANGER | |||
| DMS-153 | Growth Inhibition Assay | IC50=1.57674 μM | SANGER | |||
| SK-MEL-2 | Growth Inhibition Assay | IC50=1.71789 μM | SANGER | |||
| NCI-H1155 | Growth Inhibition Assay | IC50=1.73676 μM | SANGER | |||
| NCI-H1092 | Growth Inhibition Assay | IC50=1.76182 μM | SANGER | |||
| LU-165 | Growth Inhibition Assay | IC50=1.86476 μM | SANGER | |||
| HL-60 | Growth Inhibition Assay | IC50=1.99908 μM | SANGER | |||
| REH | Growth Inhibition Assay | IC50=2.00582 μM | SANGER | |||
| JVM-2 | Growth Inhibition Assay | IC50=2.06135 μM | SANGER | |||
| MN-60 | Growth Inhibition Assay | IC50=2.17308 μM | SANGER | |||
| SCC-15 | Growth Inhibition Assay | IC50=2.2027 μM | SANGER | |||
| SNU-C1 | Growth Inhibition Assay | IC50=2.21343 μM | SANGER | |||
| SK-MEL-1 | Growth Inhibition Assay | IC50=2.32047 μM | SANGER | |||
| TGW | Growth Inhibition Assay | IC50=2.35027 μM | SANGER | |||
| CA46 | Growth Inhibition Assay | IC50=2.75967 μM | SANGER | |||
| NCI-H23 | Growth Inhibition Assay | IC50=2.80791 μM | SANGER | |||
| MMAC-SF | Growth Inhibition Assay | IC50=2.86628 μM | SANGER | |||
| NCI-H2171 | Growth Inhibition Assay | IC50=3.03448 μM | SANGER | |||
| A704 | Growth Inhibition Assay | IC50=3.14194 μM | SANGER | |||
| DB | Growth Inhibition Assay | IC50=3.25576 μM | SANGER | |||
| NCI-H719 | Growth Inhibition Assay | IC50=3.30384 μM | SANGER | |||
| MC-CAR | Growth Inhibition Assay | IC50=3.54817 μM | SANGER | |||
| SIMA | Growth Inhibition Assay | IC50=3.58416 μM | SANGER | |||
| SW872 | Growth Inhibition Assay | IC50=3.78101 μM | SANGER | |||
| HCC1187 | Growth Inhibition Assay | IC50=3.78315 μM | SANGER | |||
| EW-13 | Growth Inhibition Assay | IC50=3.83417 μM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=4.21999 μM | SANGER | |||
| NCI-H226 | Growth Inhibition Assay | IC50=4.33606 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition Assay | IC50=4.36029 μM | SANGER | |||
| OCI-AML2 | Growth Inhibition Assay | IC50=4.5523 μM | SANGER | |||
| LU-65 | Growth Inhibition Assay | IC50=4.93033 μM | SANGER | |||
| SK-N-DZ | Growth Inhibition Assay | IC50=5.63465 μM | SANGER | |||
| NB14 | Growth Inhibition Assay | IC50=5.97135 μM | SANGER | |||
| COLO-829 | Growth Inhibition Assay | IC50=6.33359 μM | SANGER | |||
| MHH-CALL-2 | Growth Inhibition Assay | IC50=6.51508 μM | SANGER | |||
| NCI-H1770 | Growth Inhibition Assay | IC50=6.66904 μM | SANGER | |||
| ECC4 | Growth Inhibition Assay | IC50=6.82179 μM | SANGER | |||
| A498 | Growth Inhibition Assay | IC50=6.87192 μM | SANGER | |||
| DMS-79 | Growth Inhibition Assay | IC50=7.04512 μM | SANGER | |||
| P30-OHK | Growth Inhibition Assay | IC50=7.21906 μM | SANGER | |||
| D-502MG | Growth Inhibition Assay | IC50=7.9836 μM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=8.0628 μM | SANGER | |||
| U-698-M | Growth Inhibition Assay | IC50=8.29226 μM | SANGER | |||
| BB49-HNC | Growth Inhibition Assay | IC50=9.42265 μM | SANGER | |||
| ES1 | Growth Inhibition Assay | IC50=9.68956 μM | SANGER | |||
| MFM-223 | Growth Inhibition Assay | IC50=10.9927 μM | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | IC50=11.3523 μM | SANGER | |||
| EB2 | Growth Inhibition Assay | IC50=12.6881 μM | SANGER | |||
| C8166 | Growth Inhibition Assay | IC50=13.8303 μM | SANGER | |||
| ES3 | Growth Inhibition Assay | IC50=13.9977 μM | SANGER | |||
| NCI-H1650 | Growth Inhibition Assay | IC50=16.3765 μM | SANGER | |||
| Mo-T | Growth Inhibition Assay | IC50=17.4029 μM | SANGER | |||
| NB7 | Growth Inhibition Assay | IC50=17.7467 μM | SANGER | |||
| ES7 | Growth Inhibition Assay | IC50=19.5507 μM | SANGER | |||
| ES5 | Growth Inhibition Assay | IC50=21.7671 μM | SANGER | |||
| MSTO-211H | Growth Inhibition Assay | IC50=21.8858 μM | SANGER | |||
| U-87-MG | Growth Inhibition Assay | IC50=25.1966 μM | SANGER | |||
| THP-1 | Growth Inhibition Assay | IC50=29.7201 μM | SANGER | |||
| NB10 | Growth Inhibition Assay | IC50=30.2694 μM | SANGER | |||
| NH-12 | Growth Inhibition Assay | IC50=33.2017 μM | SANGER | |||
| COLO-824 | Growth Inhibition Assay | IC50=34.1006 μM | SANGER | |||
| SKM-1 | Growth Inhibition Assay | IC50=37.8422 μM | SANGER | |||
| NCI-H1838 | Growth Inhibition Assay | IC50=38.3797 μM | SANGER | |||
| RL | Growth Inhibition Assay | IC50=39.2477 μM | SANGER | |||
| COLO-800 | Growth Inhibition Assay | IC50=40.0773 μM | SANGER | |||
| KG-1 | Growth Inhibition Assay | IC50=40.8955 μM | SANGER | |||
| TUR | Growth Inhibition Assay | IC50=41.6399 μM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=41.9017 μM | SANGER | |||
| NCI-H322M | Growth Inhibition Assay | IC50=42.5984 μM | SANGER | |||
| LNCaP | Growth Inhibition Assay | IC50=91.3 nM | 25505174 | |||
| C4-2 | Growth Inhibition Assay | IC50=8 nM | 25505174 | |||
| JURKAT | Growth Inhibition Assay | 24 h | IC50=416.66 nM | 24519995 | ||
| MOLT-4 | Growth Inhibition Assay | 24 h | IC50=2853.5 nM | 24519995 | ||
| REH | Growth Inhibition Assay | 24 h | IC50=287.68 nM | 24519995 | ||
| NALM-6 | Growth Inhibition Assay | 24 h | IC50=34330 nM | 24519995 | ||
| RS 4;11 | Growth Inhibition Assay | 24 h | IC50=519.05 nM | 24519995 | ||
| 697 | Growth Inhibition Assay | 24 h | IC50=2107.1 nM | 24519995 | ||
| SIL-ALL | Growth Inhibition Assay | 24 h | IC50=199.77 nM | 24519995 | ||
| CEM | Growth Inhibition Assay | 24 h | IC50=52.18 nM | 24519995 | ||
| P12 | Growth Inhibition Assay | 24 h | IC50=39.27 nM | 24519995 | ||
| NALM-16 | Growth Inhibition Assay | 24 h | IC50=96.28 nM | 24519995 | ||
| JURKAT | Growth Inhibition Assay | 48 h | IC50=14.84 nM | 24519995 | ||
| MOLT-4 | Growth Inhibition Assay | 48 h | IC50=26.6 nM | 24519995 | ||
| REH | Growth Inhibition Assay | 48 h | IC50=44.71 nM | 24519995 | ||
| NALM-6 | Growth Inhibition Assay | 48 h | IC50=23.26 nM | 24519995 | ||
| RS 4;11 | Growth Inhibition Assay | 48 h | IC50=164.28 nM | 24519995 | ||
| 697 | Growth Inhibition Assay | 48 h | IC50=305.3 nM | 24519995 | ||
| SIL-ALL | Growth Inhibition Assay | 48 h | IC50=74.62 nM | 24519995 | ||
| CEM | Growth Inhibition Assay | 48 h | IC50=24.55 nM | 24519995 | ||
| P12 | Growth Inhibition Assay | 48 h | IC50=18.46 nM | 24519995 | ||
| NALM-16 | Growth Inhibition Assay | 48 h | IC50=63.24 nM | 24519995 | ||
| JURKAT | Growth Inhibition Assay | 72 h | IC50=3.65 nM | 24519995 | ||
| MOLT-4 | Growth Inhibition Assay | 72 h | IC50=7.39 nM | 24519995 | ||
| REH | Growth Inhibition Assay | 72 h | IC50=16.01 nM | 24519995 | ||
| NALM-6 | Growth Inhibition Assay | 72 h | IC50=1.78 nM | 24519995 | ||
| RS 4;11 | Growth Inhibition Assay | 72 h | IC50=4.38 nM | 24519995 | ||
| 697 | Growth Inhibition Assay | 72 h | IC50=74.28 nM | 24519995 | ||
| SIL-ALL | Growth Inhibition Assay | 72 h | IC50=7.2 nM | 24519995 | ||
| CEM | Growth Inhibition Assay | 72 h | IC50=5.42 nM | 24519995 | ||
| P12 | Growth Inhibition Assay | 72 h | IC50=6.37 nM | 24519995 | ||
| NALM-16 | Growth Inhibition Assay | 72 h | IC50=77.73 nM | 24519995 | ||
| Y79 | Apoptosis Assay | 1-50 nM | 12/24 h | DMSO | induced apoptosis which can be enhanced by HT | 24366665 |
| WER-Rb-1 | Apoptosis Assay | 1-50 nM | 12/24 h | DMSO | induced apoptosis which can be enhanced by HT | 24366665 |
| G7 | Growth Inhibition Assay | IC50=3.3 nM | 24204733 | |||
| G166 | Growth Inhibition Assay | IC50=7.0 nM | 24204733 | |||
| CB660 | Growth Inhibition Assay | IC50=6.4 nM | 24204733 | |||
| CB1117 | Growth Inhibition Assay | IC50=15.6 nM | 24204733 | |||
| KB-3-1 | Growth Inhibition Assay | IC50=1.48 ± 0.53 nM | 23962445 | |||
| KB-8-5-11 | Growth Inhibition Assay | IC50=5.01 ± 2.01 nM | 23962445 | |||
| KB-C-1 | Growth Inhibition Assay | IC50=16.76 ± 4.51 nM | 23962445 | |||
| KB-V-1 | Growth Inhibition Assay | IC50=281.24 ± 31.57 nM | 23962445 | |||
| OVCAR-8 | Growth Inhibition Assay | IC50=7.19 ± 3.60 nM | 23962445 | |||
| NCI-ADR-RES | Growth Inhibition Assay | IC50=1273.30 ± 191.20 nM | 23962445 | |||
| MCF7 | Growth Inhibition Assay | IC50=5.11 ± 1.47 nM | 23962445 | |||
| MCF7-FLV1000 | Growth Inhibition Assay | IC50=393.18 ± 74.83 nM | 23962445 | |||
| S1 | Growth Inhibition Assay | IC50=24.30 ± 4.75 nM | 23962445 | |||
| S1-M1-80 | Growth Inhibition Assay | IC50=261.06 ± 48.25 nM | 23962445 | |||
| CORL-23/P | Growth Inhibition Assay | IC50=4.38 ± 1.25 nM | 23962445 | |||
| CORL-23/R | Growth Inhibition Assay | IC50=5.16 ± 1.83 nM | 23962445 | |||
| NIH3T3 | Growth Inhibition Assay | IC50=40.60 ± 4.97 nM | 23962445 | |||
| NIH3T3-G185 | Growth Inhibition Assay | IC50=2413.40 ± 423.66 nM | 23962445 | |||
| pcDNA-HEK293 | Growth Inhibition Assay | IC50=2.75 ± 0.67 nM | 23962445 | |||
| MDR19-HEK293 | Growth Inhibition Assay | IC50=85.50 ± 13.67 nM | 23962445 | |||
| R482-HEK293 | Growth Inhibition Assay | IC50=25.97 ± 4.95 nM | 23962445 | |||
| MRP1-HEK293 | Growth Inhibition Assay | IC50=2.99 ± 1.49 nM | 23962445 | |||
| SF188 | Growth Inhibition Assay | 10-100 nM | 24-96 h | DMSO | inhibits cell growth in both time- and concentration- depedent manner | 23887645 |
| T98G | Growth Inhibition Assay | 10-100 nM | 24-96 h | DMSO | inhibits cell growth in concentration- depedent manner | 23887645 |
| DU145 | Growth Inhibition Assay | DMSO | IC50∼60 nM | 23884428 | ||
| LNCaP | Growth Inhibition Assay | DMSO | IC50∼75 nM | 23884428 | ||
| PC3 | Growth Inhibition Assay | DMSO | IC50∼175 nM | 23884428 | ||
| RT4 | Growth Inhibition Assay | IC50=27.21 nM | 23792639 | |||
| 5637 | Growth Inhibition Assay | IC50=45.47 nM | 23792639 | |||
| T24 | Growth Inhibition Assay | IC50=79.12 nM | 23792639 | |||
| MCF7 | Function Assay | 100 nM | 1 h | DMSO | reduces the induction of Greb1, Sgk1, Ps2, Serpina3, and Wisp2 | 23770244 |
| KB-V1 | Growth Inhibition Assay | IC50=3.92 μM | 23593196 | |||
| Hec50co | Growth Inhibition Assay | IC50=5 nM | 23146687 | |||
| MDA-MB-468 | Apoptosis Assay | 1/5/10 nM | 24/48/72 h | DMSO | induces apoptosis in a dose-dependent manner | 23144294 |
| MCF10A | Apoptosis Assay | 1/5/10 nM | 24/48/72 h | DMSO | induces apoptosis in a dose-dependent manner | 23144294 |
| Huh-7 | Growth Inhibition Assay | 1/10/100/1000 nM | 48 h | decreases the cell viability dose-dependently | 22745587 | |
| Daoy | Growth Inhibition Assay | 1.875-240 nM | 72 h | DMSO | IC50=5 nM | 22390279 |
| ONS-76 | Growth Inhibition Assay | 1.875-240 nM | 72 h | DMSO | IC50=7.5 nM | 22390279 |
| SUM 149 | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| MDA-MB-231 | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| HR5 | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| BT-474-M1 | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| AU565 | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| T47D | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| MCF7 | Growth Inhibition Assay | 0-100 nM | 72 h | inhibits the cell viability in a dose-dependent mannar | 22309939 | |
| HCT116p53(+/+) | Growth Inhibition Assay | 10-1000 nM | 24/48 h | inhibits cell proliferation completely at 25 nM | 22262171 | |
| HCT116p53(-/-) | Growth Inhibition Assay | 10-1000 nM | 24/48 h | inhibits cell proliferation completely at 25 nM | 22262171 | |
| HeLa | Growth Inhibition Assay | 10-100 nM | 48 h | DMSO | IC50=52.9 nM | 22080235 |
| HeLa | Growth Inhibition Assay | 10-100 nM | 72 h | DMSO | IC50=50.5 nM | 22080235 |
| GBC | Growth Inhibition Assay | 72 h | IC50=14.78 nM | 21965739 | ||
| GB-CL-1 | Growth Inhibition Assay | 72 h | IC50=5.22 nM | 21965739 | ||
| Mz-ChA-2 | Growth Inhibition Assay | 72 h | IC50=3.31 nM | 21965739 | ||
| TGBC1-TKB | Growth Inhibition Assay | 144 h | IC50=6.72 nM | 21965739 | ||
| Wittier | Growth Inhibition Assay | 72 h | IC50=3.26 nM | 21965739 | ||
| H-1 | Growth Inhibition Assay | 72 h | IC50=9.54 nM | 21965739 | ||
| HuH-28 | Growth Inhibition Assay | 72 h | IC50=11.19 nM | 21965739 | ||
| NEC | Growth Inhibition Assay | 72 h | IC50=9.98 nM | 21965739 | ||
| REB | Growth Inhibition Assay | 72 h | IC50=13.51 nM | 21965739 | ||
| CC-LP-1 | Growth Inhibition Assay | 72 h | IC50=5.84 nM | 21965739 | ||
| CC-SW-1 | Growth Inhibition Assay | 72 h | IC50=9.55 nM | 21965739 | ||
| EGI-1 | Growth Inhibition Assay | 72 h | IC50=10.72 nM | 21965739 | ||
| Sk-ChA-1 | Growth Inhibition Assay | 72 h | IC50=17.2 nM | 21965739 | ||
| TFK-1 | Growth Inhibition Assay | 72 h | IC50=13.45 nM | 21965739 | ||
| 786-O | Growth Inhibition Assay | 5-80 nM | 96 h | HCl | suppresses the proliferation in a dose-dependent manner with IC50 values of 2 to 20 nM | 21642374 |
| A498 | Growth Inhibition Assay | 5-80 nM | 96 h | HCl | suppresses the proliferation in a dose-dependent manner with IC50 values of 2 to 20 nM | 21642374 |
| ACHN | Growth Inhibition Assay | 5-80 nM | 96 h | HCl | suppresses the proliferation in a dose-dependent manner with IC50 values of 2 to 20 nM | 21642374 |
| Caki-1 | Growth Inhibition Assay | 5-80 nM | 96 h | HCl | suppresses the proliferation in a dose-dependent manner with IC50 values of 2 to 20 nM | 21642374 |
| SN12C | Growth Inhibition Assay | 5-80 nM | 96 h | HCl | suppresses the proliferation in a dose-dependent manner with IC50 values of 2 to 20 nM | 21642374 |
| HMC-1.1 | Growth Inhibition Assay | 1-1000 nM | 72 h | inhibits the cell proliferation in a dose-dependent manne | 21242189 | |
| HMC-1.2 | Growth Inhibition Assay | 1-1000 nM | 72 h | inhibits the cell proliferation in a dose-dependent manne | 21242189 | |
| C2 | Growth Inhibition Assay | 1-1000 nM | 72 h | inhibits the cell proliferation in a dose-dependent manne | 21242189 | |
| CHP-212 | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| IMR-32 | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| Kelly | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| SH-EP | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| SH-SY5Y | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| SK-N-AS | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| SK-N-BE | Growth Inhibition Assay | 1-125 nM | 24-120 h | inhibits the cell proliferation in both time- and dose-dependent manne | 21169242 | |
| KG1 | Growth Inhibition Assay | 1/10/100 nM | 72 h | DMSO | inhibits the cell proliferation in both time- and dose-dependent manne | 19458358 |
| U937 | Growth Inhibition Assay | 1/10/100 nM | 72 h | DMSO | inhibits the cell proliferation in both time- and dose-dependent manne | 19458358 |
| CAL62 | Growth Inhibition Assay | 0.1-100 nM | 72 h | DMSO | EC50=1.4 nM | 19223553 |
| OCUT-1 | Growth Inhibition Assay | 0.1-100 nM | 72 h | DMSO | EC50=2.3 nM | 19223553 |
| 8505C | Growth Inhibition Assay | 0.1-100 nM | 72 h | DMSO | EC50=3.2 nM | 19223553 |
| ACT-1 | Growth Inhibition Assay | 0.1-100 nM | 72 h | DMSO | EC50=5.4 nM | 19223553 |
| SW1736 | Growth Inhibition Assay | 0.1-100 nM | 72 h | DMSO | EC50=5.6 nM | 19223553 |
| HEK293 | Function assay | 1 hr | Binding affinity to PLK1 (unknown origin) expressed in HEK293 cells after 1 hr by proprietary competition assay, Ki = 0.00022 μM. | 26191363 | ||
| HEK293T | Antiproliferative assay | 72 hrs | Antiproliferative activity against HEK293T cells measured after 72 hrs by CellTiter-Blue assay, IC50 = 0.001 μM. | 28792760 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CellTiter-Blue assay, IC50 = 0.001 μM. | 28792760 | ||
| MM1S | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MM1S cells measured after 72 hrs by CellTiter-Blue assay, IC50 = 0.001 μM. | 28792760 | ||
| TY82 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human TY82 cells after 72 hrs by CCK8 assay, IC50 = 0.001 μM. | 28586718 | ||
| NMC-797 | Cytotoxicity assay | 3 days | Cytotoxicity against BRD4 dependent human NMC-797 cells assessed as cell viability after 3 days by ATPlite assay, IC50 = 0.0107 μM. | 26985285 | ||
| MV4-11 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MV4-11 cells after 24 hrs by CellTiter-Blue assay, GI50 = 0.0152 μM. | 26191363 | ||
| BL21(DE3) | Function assay | 60 mins | Inhibition of recombinant human N-terminal His6-tagged BRD4 expressed in Escherichia coli BL21(DE3) cells using biotinylated histone H4 peptide as substrate after 60 mins by AlphaScreen assay, IC50 = 0.025 μM. | 28195723 | ||
| BL21(DE3) | Function assay | Inhibition of human N-terminal His6-tagged BRD4-BD1 (44 to 168 residues) expressed in Escherichia coli BL21 (DE3) cells using protein thermal shift dye as fluorescence probe by differential scanning fluorimetry, IC50 = 0.025 μM. | 28586718 | |||
| HuH7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay, GI50 = 0.028 μM. | 29220793 | ||
| HeLa | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay, GI50 = 0.034 μM. | 29220793 | ||
| HL60 | Cytotoxicity assay | 3 days | Cytotoxicity against BRD4 dependent human HL60 cells assessed as cell viability after 3 days by ATPlite assay, IC50 = 0.0365 μM. | 26985285 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay, GI50 = 0.057 μM. | 29220793 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay, GI50 = 0.067 μM. | 29220793 | ||
| K562 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay, GI50 = 0.068 μM. | 29220793 | ||
| MDA-MB-23 | Function assay | 6 hrs | Inhibition of PLK1 in human MDA-MB-23 cells assessed as decrease in TCTP phosphorylation after 6 hrs by Western blot method, IC50 = 0.1 μM. | 28792760 | ||
| HEK293T | Function assay | 6 hrs | Inhibition of PLK1 in HEK293T cells assessed as decrease in TCTP phosphorylation after 6 hrs by Western blot method, IC50 = 0.1 μM. | 28792760 | ||
| NCI-H1975 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H1975 cells after 72 hrs by CCK8 assay, GI50 = 0.23 μM. | 29220793 | ||
| BL21(DE3) | Function assay | 4 hrs | Inhibition of JQ1-FITC binding to His6-tagged BRD4-BD1 (unknown origin) expressed in Escherichia coli BL21 (DE3)-codon plus-RIL cells incubated in dark for 4 hrs by fluorescence anisotropy assay, IC50 = 0.25 μM. | 28586718 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | |||
| Fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | |||
| MG 63(6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | |||
| Fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | |||
| DU145 | Apoptosis assay | 100 nM | 24 hrs | Induction of apoptosis in human DU145 cells assessed as increase in PARP cleavage at 100 nM after 24 hrs by immunoblotting method | 25685941 | |
| HeLa | Function assay | 100 nM | Inhibition of PLK1 Thr210 phosphorylation in human HeLa cells at 100 nM by immunoblotting method | 25685941 | ||
| DU145 | Function assay | 100 nM | Inhibition of PLK1 protein accumulation in human DU145 cells at 100 nM by immunoblotting method | 25685941 | ||
| HeLa | Function assay | 100 nM | Inhibition of PLK1 protein accumulation in human HeLa cells at 100 nM by immunoblotting method | 25685941 | ||
| HeLa | Function assay | 100 nM | 18 hrs | Induction of monopolar mitotic spindles in human HeLa cells at 100 nM incubated for 18 hrs by indirect immunofluorescence microscopy | 25685941 | |
| HeLa | Apoptosis assay | 100 nM | 24 hrs | Induction of apoptosis in human HeLa cells assessed as increase in PARP cleavage at 100 nM after 24 hrs by immunoblotting method | 25685941 | |
| PC3 | Function assay | 100 nM | 18 hrs | Induction of monopolar mitotic spindles in human PC3 cells at 100 nM incubated for 18 hrs by indirect immunofluorescence microscopy | 25685941 | |
| DU145 | Function assay | 100 nM | Inhibition of PLK1 Thr210 phosphorylation in human DU145 cells at 100 nM by immunoblotting method | 25685941 | ||
| Cliquez pour voir plus de données expérimentales sur les lignées cellulaires | ||||||
| Poids moléculaire | 521.66 | Formule | C28H39N7O3 |
Stockage (À partir de la date de réception) | |
|---|---|---|---|---|---|
| N° CAS | 755038-02-9 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | N/A | Smiles | CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C | ||
|
In vitro |
Ethanol : 104 mg/mL
DMSO
: 96 mg/mL
(184.02 mM)
Water : Insoluble |
|
In vivo |
|||||
Étape 1 : Entrez les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)
Étape 2 : Entrez la formulation in vivo (Ceci nest que le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, ajouter ensuiteμL PEG300, mélanger et clarifier, ajouter ensuiteμL Tween 80, mélanger et clarifier, ajouter ensuite μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, ajouter ensuite μL Huile de maïs, mélanger et clarifier.
Remarque : 1. Assurez-vous que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue lors de lajout précédent est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie peuvent être utilisées pour faciliter la dissolution.
| Fonctionnalités |
The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
|
|---|---|
| Targets/IC50/Ki |
c-Myc
PLK1
(Cell-free assay) 0.83 nM
PLK2
(Cell-free assay) 3.5 nM
PLK3
(Cell-free assay) 9.0 nM
BRD4
(Cell-free assay) 37 nM(Kd)
|
| In vitro |
BI 2536 bloque les activités de Plk2 et Plk3 dans une moindre mesure avec des IC50 de 3,5 nM et 9,0 nM, respectivement. Dans les cellules HeLa, ce traitement composé allant de 10 à 100 nM entraîne le blocage du recrutement de la γ-tubuline et la phosphorylation d'Apc6 aux centrosomes mitotiques, l'inhibition de la libération de la cohésine des bras chromosomiques, l'induction de fuseaux monopolaires, ainsi qu'une gamme d'autres processus mitotiques dont on sait qu'ils dépendent de Plk1. Ce traitement chimique conduit à l'arrêt des cellules HeLa en G2/M, puis à un pic d'ADN sub-G1 indiquant une dégradation de l'ADN et une Apoptosis, et à l'accumulation de fragments de PARP p85 clivés de manière concentration-dépendante. Il inhibe la croissance d'un panel de 32 lignées de cellules cancéreuses humaines avec des EC50 de 2-25 nM, tout en bloquant la prolifération des cellules hTERT-RPE1 en croissance exponentielle, des cellules endothéliales de la veine ombilicale humaine (HUVECs) et des cellules rénales de rat normales (NRK) avec des EC50 de 12-31 nM. L'inhibition de Plk1 par ce composé réduit la croissance et la viabilité des cellules de carcinome thyroïdien anaplasique (ATC) telles que CAL62, OCUT-1, SW1736, 8505C et ACT-1 avec des valeurs d'EC50 de 1,4-5,6 nM. |
| Kinase Assay |
Essai kinase in vitro de Plk1
|
|
La Plk1 humaine recombinante (résidus 1-603) est exprimée sous forme de protéine de fusion N-terminale, étiquetée GST, avec un système d'expression baculoviral et purifiée par chromatographie d'affinité avec de l'agarose-glutathion. Les tests d'activité enzymatique pour Plk1 sont effectués en présence de BI 2536 dilué en série avec 20 ng de kinase recombinante et 10 μg de caséine de lait bovin comme substrat. Les réactions de kinase sont effectuées dans un volume final de 60 μL pendant 45 minutes à 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Les réactions sont terminées par l'ajout de 125 μL de TCA à 5% glacé. Après transfert des précipités sur des plaques filtrantes en cellulose à ester mixte Multi-Screen, les plaques sont lavées avec 1% de TCA et quantifiées radiométriquement. La courbe dose-réponse est utilisée pour calculer la valeur IC50.
|
|
| In vivo |
Administré par voie intraveineuse une ou deux fois par semaine, BI 2536 est très efficace dans divers modèles de xénogreffes avec une tolérance acceptable en inhibant la prolifération cellulaire par un arrêt mitotique, et par la suite en induisant la mort des cellules tumorales. L'administration de ce composé à 50 mg/kg une ou deux fois par semaine inhibe significativement la croissance des xénogreffes HCT 116 avec un T/C de 15% et 0,3% respectivement. Ce traitement chimique deux fois par semaine entraîne également une excellente croissance tumorale dans les modèles BxPC-3 et A549 avec un T/C de 5% et 14% respectivement. |
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9 p-HH3 / PARP / Myc / p-Myc pMEK / MEK / pERK / ERK / pRSK1 / RSK1 pPlk1 / Plk1 / pMyt1 Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2 |
|
27699933 |
| Immunofluorescence | p-H2AX / propidium iodide Pericentrin / α-tubulin |
|
22309939 |
| Growth inhibition assay | Cell viability |
|
21772266 |
(données de https://clinicaltrials.gov, mis à jour le 2024-05-22)
| Numéro NCT | Recrutement | Conditions | Sponsor/Collaborateurs | Date de début | Phases |
|---|---|---|---|---|---|
| NCT02215044 | Terminated | Pancreatic Neoplasms |
Boehringer Ingelheim |
June 2007 | Phase 1 |
| NCT02211833 | Completed | Carcinoma Non-Small-Cell Lung |
Boehringer Ingelheim |
October 2006 | Phase 1 |
| NCT00701766 | Completed | Leukemia Myeloid Acute |
Boehringer Ingelheim |
October 2006 | Phase 2 |
| NCT00706498 | Completed | Prostatic Neoplasms |
Boehringer Ingelheim |
September 2006 | Phase 2 |
| NCT00376623 | Completed | Carcinoma Non-Small-Cell Lung |
Boehringer Ingelheim |
July 25 2006 | Phase 2 |
| NCT02211872 | Completed | Neoplasms |
Boehringer Ingelheim |
August 2004 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
Si vous avez dautres questions, veuillez laisser un message.
Question 1:
We need to use it in preclinical studies using mice; how to formulate this compound for the in vivo study?
Réponse :
For in vivo study, DMSO should not be more than 5% because of the toxicity. It can be formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference: (Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6